Payment overview · 2025
General Payments
$1,506.97
74 reported records · 19 companies
Healthcare provider profile · identity verified
Nilar U, M.D
Allopathic & Osteopathic Physicians|General Practice · WESTMINSTER, MD · NPI 1760416069
Verified facts
What the public records show
CMS Open Payments records show Nilar U, M.D received $1,506.97 in general payments during 2025 across 74 reported records.
PFIZER INC. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $286.78 | 19.0% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $189.63 | 12.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.79 | 11.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.19 | 6.5% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.46 | 6.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $87.23 | 5.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.50 | 5.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.62 | 4.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.50 | 4.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $62.54 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.91 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.98 | 3.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $40.21 | 2.7% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.37 | 1.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.77 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.22 | 1.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.91 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.42 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.94 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,506.97 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.44 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $168.44 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.54 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $118.34 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $118.34 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $118.34 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.20 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $111.74 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $111.74 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.46 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $86.50 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $77.89 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $73.62 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.15 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $63.50 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $62.54 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.91 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.81 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $40.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $40.21 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $28.37 | 2 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $28.37 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 101 |
| Lisinopril | Lisinopril | 252 | 74 |
| Alendronate Sodium | Alendronate Sodium | 249 | 73 |
| Losartan Potassium | Losartan Potassium | 212 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 58 |
| Metformin Hcl | Metformin Hcl | 173 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 173 | 20 |
| Tramadol Hcl | Tramadol Hcl | 164 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 40 |
| Omeprazole | Omeprazole | 134 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 38 |
| Alprazolam | Alprazolam | 132 | 25 |
| Gabapentin | Gabapentin | 128 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 48 |
| Simvastatin | Simvastatin | 124 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 38 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 118 | 31 |
| Sertraline Hcl | Sertraline Hcl | 109 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 106 | 83 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 104 | 14 |
| Montelukast Sodium | Montelukast Sodium | 98 | 32 |
| Furosemide | Furosemide | 87 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 26 |
| Lorazepam | Lorazepam | 72 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 21 |
| Cephalexin | Cephalexin | 69 | 55 |
| Trazodone Hcl | Trazodone Hcl | 66 | 27 |
| Buspirone Hcl | Buspirone Hcl | 64 | 16 |
| Famotidine | Famotidine | 63 | 22 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Cefuroxime | Cefuroxime Axetil | 62 | 50 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 24 |
| Azithromycin | Azithromycin | 59 | 48 |
| Lovastatin | Lovastatin | 50 | 15 |
| Eliquis | Apixaban | 48 | 15 |
| Fluconazole | Fluconazole | 48 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 13 |
| Telmisartan | Telmisartan | 47 | 13 |
| Prednisone | Prednisone | 46 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 15 |
| Ozempic | Semaglutide | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 15 |
| Mupirocin | Mupirocin | 41 | 27 |
| Methylprednisolone | Methylprednisolone | 40 | 32 |
| Nystatin | Nystatin | 39 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 15 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 36 |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | 13 |
| Clotrimazole | Clotrimazole | 30 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | 12 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Ibuprofen | Ibuprofen | 22 | 11 |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,506.97 · 74 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, Belbuca, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SYNTHROID, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error